Poster Session 2 – Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT
   
  Detection/Diagnosis - Pathology: Circulating BioMarkers and ctDNA
P2-01-01 Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC)
Hensing WL, Gerratana L, Clifton K, Velimirovic M, Shah A, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Bagegni NA, Opyrchal M, Ademuyiwa FO, Ron B, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. Washington University in St. Louis, Saint Louis, MO; Northwestern University, Chicago, IL; Massachusetts General Hospital, Boston, MA.
P2-01-02 A whole blood assay to identify breast cancer: Interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX breast cancer test
Bundred N, Fuh K, Asgarian N, Brown S, Simonot D, Wang X, Shepherd R, Quan ML, Docktor BJ, Maxwell A, Kirwan C, Hollingsworth A (retired), Morris D, Rinker K. Manchester University NHS Foundation Trust, Manchester, United Kingdom; Syantra Inc., Calgary, AB, Canada; Alberta Cancer Research Biobank, Calgary, AB, Canada; Alberta Health Services, Calgary, AB, Canada; University of Calgary, Calgary, AB, Canada; University of Manchester, Manchester, United Kingdom; Mercy Health, Oklahoma City, OK;; Tom Baker Cancer Centre, Calgary, AB, Canada.
P2-01-03 Elucidating the biology of circulating tumor DNA (ctDNA) shedding across receptor subtypes in high-risk early-stage breast cancer
Sayaman RW, Wolf DM, Yau C, Brown Swigart L, Hirst GL, Sit L, O'Grady N, Delson AL, I-SPY2 Investigators, Esserman L, van 't Veer LJ, Magbanua MJM. University of California San Francisco, San Francisco, CA.
P2-01-04 Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer
Zhang Q, D'Amico P, Qin W, Jiao J, Davis AA, Gerratana L, Jacob SL, Zhang Y, Donahue J, Qiang W, Shah AN, Behdad A, Flaum L, Gradishar W, Platanias LC, Cristofanilli M. Department of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine, Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Urology, Air Force Medical University, Xi'an, China; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, St. Louis, MO; Department of Medicine, University of Udine, Udine, Italy; CLP - Chemistry of Life Processes Institute, Northwestern University, Chicago, IL; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
P2-01-05 Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease
Sharma P, Stecklein SR, Kimler BF, Yoder R, Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab J, Home T, Hyter S, Isakova K, Pathak HB, Godwin AK. University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; University of Kansas Medical Center, Lee's Summit, MO.
P2-01-06 Detection of circulating tumor DNA post neoadjuvant chemotherapy using a personalized assay is associated with disease relapse
Agostinetto E, Cailleux F, Lambertini M, Rothé F, Wu H-T, Balcioglu M, Sethi H, Vincent D, Viglietti G, Gombos A, Papagiannis A, Veys1 I Awada A, Sotiriou C, Kalashnikova E, Aleshin A, Larsimont D, Venet D, Ignatiadis M. Institut Jules Bordet, Brussels, Belgium; Ospedale San Martino IRCCS, Genova, Italy; Natera, Inc., Austin, TX.
P2-01-07 Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach
Janni W, Huober J, Huesmann S, Pipinikas C, Braun T, Müller V, Marsico G, Fink A, Freire-Pritchett P, Koretz K, Knape C, deGregorio A, Rack B, Friedl TWP, Wiesmueller L, Möller P, Howarth K, Pantel K, Rosenfeld N. University Hospital Ulm, Ulm, Germany; Inivata Ltd, Cambridge, United Kingdom; University Hospital Hamburg, Hamburg, Germany.
P2-01-08 Esr1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer
Zhang Q, Jiao J, D'Amico P, Davis AA, Qin W, Gerratana L, Jacob SL, Zhang Y, Donahue J, Qiang W, Shah AN, Flaum L, Gradishar W, Platanias LC, Cristofanilli M. Department of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine, Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Urology, Air Force Medical University, Xi'an, China; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, St. Louis, MO; Department of Medicine, University of Udine, Udine, Italy; CLP - Chemistry of Life Processes Institute, Northwestern University, Chicago, IL, United States, Chicago, IL.
P2-01-09 Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status
Chen TW-W, Hsiao W, Dai M-S, Lin C-H, Chang D-Y, Chen I-C, Wang M-Y, Huang L-Y, Chang S-H, Huang S-M, Cheng A-L, Tan KT, Lu Y-S. National Taiwan University Hospital, Taipei, Taiwan; ACT Genomics, Taipei, Taiwan; Tri-Service General Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei, Taiwan.
P2-01-10 Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery
Garcia-Murillas I, Cutts RJ, Ulrich L, Beaney M, Robert M, Coakley M, Bunce C, WalshCrestani G, Hrebien S, Kalashnikova E, Wu H-T, Dashner S, Sethi H, Aleshin A, Ring A, Okines A, Smith IE, Dowsett M, Barry P, Turner NC. The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom; Breast Unit, Royal Marsden Hospital, London, United Kingdom; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Clinical Trials Unit, Royal Marsden Hospital, London, United Kingdom; Natera Inc, Austin, TX; Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom.
P2-01-11 Single-cell sequencing of the blood T cell repertoire before and after trastuzumab treatment in early stage HER2+ breast cancer
Vivian J, Walter K, Drabek E, Haaser N, Levin MK, San Roman Rodriguez E, Peck K, Nguyen N, Millward C, Benjamin J, Robinson WH, O'Shaughnessy JA. Atreca, San Carlos, CA; Baylor University, Waco, TX.
P2-01-12 Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study
Darlix A, Pouderoux S, Thezenas S, Bievelez A, Jacot W, Cayrefourcq L, Menjot-de-Champfleur N, Leaha C, Alix-Panabières C. Department of Medical Oncology, Institut régional du Cancer de Montpellier, Institut de Génomique Fonctionnelle, INSERM, CNRS, University of Montpellier, Montpellier, France; Department of Medical Oncology, Institut régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Biometrics Unit, Institut régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Laboratory of Rare Human Circulating Cells, CREEC, MIVEGEC, CNRS, IRD, University Medical Center of Montpellier, University of Montpellier, Montpellier, France; Department of Neuroradiology, University of Montpellier, CHU Montpellier, Montpellier, France; Department of Pathology, Institut régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
P2-01-13 Longitudinal circulating tumor DNA (ctDNA) monitoring by digital droplet PCR (ddPCR) in metastatic breast cancer
Higashiyama N, Williams L, McCue B, Kuriakose A, Tran T, Gonzalez S, Licerio M, Chenault C, Dowst H, Hilsenbeck S, Ellis M, Lim B, Miles G. Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
P2-01-14 The multi switching activity of neutrophils in the circulation of patients with early breast cancer
Ramessur A, Ambasager B, Malanchi I, Coombes RC. Imperial College London, London, United Kingdom; Francis Crick Institute, London, United Kingdom.
P2-01-15 Developing highly sensitive high NGS data efficient ctDNA detection assays for breast cancer surveillance
Fu A, Cui W, Ton MV, Wang K, Gu W, Li T, Parsons HA, Liu MC, Sledge GW. NVIGEN Inc., San Jose, CA; UC Davis Medical Center, Davis, CA; Dana-Farber Cancer Institute, Boston, CA; The Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA.
P2-01-16 Targeted sequencing of plasma-derived vs. urinary cfDNA from patients with triple negative breast cancer
Herzog H, Aktas B, Nel I. University of Leipzig, Medical Center, Department of Gynaecology, Leipzig, Germany.
P2-01-17 Circulating tumor cell count and levels of circulating tumor DNA are complementary prognostic biomarkers in metastatic breast cancer - A pilot study
Verschoor N, Jongbloed EM, Kraan J, de Weerd V, Van NM, Jager A, Sleijfer S, Wilting SM, Martens JWM. Erasmus Medical Centre, Rotterdam, Netherlands.
P2-01-18 Orthogonal assessment of PIK3CA and ESR1 mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2- advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology
Fuentes Antras J, García-Barberán V, Moreno F, Sloane H, López-Cade I, De Luna A, Pascual A, Ramirez-Ruda C, Lorca V, Flores P, Perez-Segura P, Ocaña A, Preston J, Quinn H, Jones F, Garcia-Saenz JA. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain; Sysmex Inostics, Baltimore, MD.
   
  Detection/Diagnosis - Pathology: Circulating Tumor Cells
P2-02-01 Stage IV stratification using circulating tumor cells (CTCs) enumeration modeling: A retrospective analysis of the MONARCH 2 study
Gerratana L, Kocherginsky M, Davis AA, D’Amico P, Reduzzi C, Zhang Q, Puglisi F, Cristofanilli M. CRO Aviano National Cancer Institute, Aviano, Italy; Northwestern University, Chicago, IL; Washington University in St. Louis, St. Louis, MO.
P2-02-02 Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer
Alkhafaji S, Wolf D, Magbanua M, Van 't Veer L, Park J, Esserman LJ, Mukhtar RA. University of California, San Francisco, San Francisco, CA.
P2-02-03 Circulating tumor cells (CTCs), CTC heterogeneity and distinct morphological CTC subtypes predict worse survival in metastatic breast cancer (MBC)
O'Shaughnessy JA, Levin MK, San Roman Rodriguez E, Lu J, Jones JT, Anderson AKL, Tubbs A, Schonhoft JD, Wenstrup R. Baylor University Medical Center, US Oncology, Texas Oncology, Dallas, TX; Baylor Scott & White Research Institute, Dallas, TX; Epic Sciences, San Diego, CA.
P2-02-04 In early breast cancer, the ratios of neutrophils, monocyctes and platelets to lymphocytes significantly correlate with the presence of subsets of circulating tumor cells in blood and disseminated tumor cells in the bone marrow
Kasimir-Bauer S, Karaaslan E, Hars O, Bittner A-K, Hoffmann O, Kimmig R. University Hospital Essen, Essen, Germany; Olaf Hars Wissenschaft, Berlin, Germany.
P2-02-05 Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer
Zhang Q, Qin W, D'Amico P, Davis AA, Jiao J, Gerratana L, Jacob SL, Zhang Y, Donahue J, Qiang W, Shah AN, Behdad A, Flaum L, Gradishar W, Platanias LC, Cristofanilli M. Department of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine, Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Urology, Air Force Medical University, Xi'an, China; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, St. Louis, MO; Department of Medicine, University of Udine, Udine, Italy; CLP - Chemistry of Life Processes Institute, Northwestern University, Chicago, IL; Department of Medicine, Division of Hematology and Oncology, Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
P2-02-06 Her2-low ctcs in breast cancer: Pipeline for phenotypic driven, single-cell collection and molecular analysis
D'Amico P, Reduzzi C, Qiang W, Zhang Q, Gerratana L, Shah AN, Davis AA, Kang A, Shi M, Zhang Y, Jacob S, Behdad A, Curigliano G, Cristofanilli M. Northwestern University, Chicago, IL; Washington University, St. Louis, MO; Istituto Europeo di Oncologia, Milano, Italy.
P2-02-07 Unbiased liquid biopsy in breast cancer patients utilizing novel light sheet microscopy of circulating tumor cells. Proof of concept in 10 patients and 13 controls
Tannenbaum S, Hsu E, Reddy A, Keilich S, Tafas T. UCONN Health, Farmington, CT; QCDx LLC, Farmington, CT.
   
  Detection/Diagnosis: Detection/Diagnosis - Other
P2-03-01 Changes in breast cancer presentation during Covid-19: Experience in an Urban Academic Center
Guth AA, Diskin B, Schnabel F, Pourkey N, Axelrod D, Shapiro R. NYU Langone Medical Center, New York, NY.
P2-03-02 Detection of insulin receptor isoforms by mass spectrometry in breast cancer
Zhang X, Higgins L, Markowski T, Yang T-Y, Wragge J, Murray K, Witthuhn B, Barrios A, Yee D. Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Center for Mass Spectrometry and Proteomics, University of Minnesota, Minneapolis, MN; California State University Dominguez Hills, Carson, CA.
P2-03-03 The comparison of genomic alteration characteristics of young women with breast cancer between Chinese and Western population
Liu H, Yu J, Xu Z, Wang F, Li Y, Zhang S, Wang B, Yang B, Li X. Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; OrigiMed, Shanghai, China.
P2-03-04 Characteristics and clinical differences of breast cancer patients with negative or low HER2 expression
Voutsadakis I, Rosso C. Sault Area Hospital, Sault Ste Marie, ON, Canada; Algoma University, Sault Ste Marie, ON, Canada.
   
  Tumor Cell and Molecular Biology: Cell Cycle Regulation
P2-04-01 Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
Liu Q, Cai Z, Wang J, Li Y, Wong LL. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
   
  Tumor Cell and Molecular Biology: Cellular Mechanisms
P2-05-01 Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas
Kern J, Tilston-Lunel A, Federico A, Ning B, Peppler G, Stampouloglou E, Lenburg M, Beane J, Monti S, Varelas X. Boston University, Boston, MA.
P2-05-02 Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development
Li M, Low KH, Bui T, Hunt KK, Keyomarsi K. MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
   
  Tumor Cell and Molecular Biology: DNA Damage and Repair
P2-06-01 Parp inhibition sensitizes brca deficient cancer cell lines and tumors to clinical x-ray and proton irradiation
Ben Kacem M, Bright SJ, Turner BX, Flint DB, Manandhar M, Martinus D, Sawakuchi GO, Shaitelman SF. MD Anderson, Houston, TX.
P2-06-02 The condensin core subunit, SMC2 (structural maintenance of chromosomes 2), is necessary for the growth and genomic stability of triple negative breast cancer cells
Ventura J, Webb B, Keri R. Cleveland Clinic Lerner Research Institute, Cleveland, OH.
P2-06-03 Obesity is associated with DNA damage in the breast epithelium of BRCA1 and BRCA2 mutation carriers: A role for estrogens & strategies for prevention
Bhardwaj P, Iyengar NM, Oshchepkova S, Piloco P, Bareja R, Elemento O, Giri DD, Pollak M, Morrow M, Spector JA, Brown KA. Weill Cornell Medicine, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; McGill University, Montreal, QC, Canada.
P2-06-04 Pathognomonic long molecule footprints of backup repair pathways in homologous recombination deficient cancers
Setton J, Hadi K, Tian H, Da Cruz Paula A, Rosiene J, Choo Z-N, Behr J, Yao X, Elemento O, Weigelt B, Riaz N, Reis-Filho JS, Imielinski M, Powell SN. MSKCC, New York, NY; Weill Cornell Medicine, New York, NY.
   
  Prognostic and Predictive Factors - Predictive Biomarkers for Combined Modality Therapies
P2-07-01 Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)
Davis A, Luo J, Zheng T, Tan L, Wang A, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya L, Peterson L, Luo S, King BL, Jia S, Yu J, Du P, Krishnamurthy J, Ma CX. Washington University School of Medicine, St. Louis, MO; Predicine, Inc, Hayward, CA; University of Nebraska Medical Center, Omaha, NE.
P2-07-02 Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
Velimirovic M, Gerratana L, Davis AA, Hensing WL, Clifton K, Shah AN, D'Amico P, Dai CS, Denault EN, Ma CX, Wander SA, Juric D, Cristofanilli M, Chabner BA, Bardia A. Department Of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Medicine, University of Udine, Udine, Italy; Department of Medicine, Division of Hematology and Oncology, Washington University in St. Louis, St. Louis, MO; Department of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
P2-07-03 Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic  response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer
Waks AG, Huang Y, Hether T, Ogayo ER, Kadel S, Alberti J, Tolaney SM, Krop IE, Divakar P, Metzger O, O'Donnell ML, Church S, Winer EP, Guerriero JL, Mittendorf EA. Dana-Farber Cancer Institute, Boston, MA; NanoString Technologies, Seattle, WA; Brigham and Women's Hospital, Boston, MA.
P2-07-04 Analysis of host inflammatory and estrogen biomarkers in JAKEE: A phase II trial of the JAK inhibitor ruxolitinib in combination with exemestane for estrogen receptor-positive metastatic breast cancer
Makhlin I, McAndrew N, Wileyto EP, Clark A, Holmes R, Bottalico LN, Jeschke GR, Fox KR, Domcheck SM,1 Matro JM, Bradbury AR, Shih N, Feldman MD, Hexner EO, Bromberg JF, DeMichele A. University of Pennsylvania, Philadelphia, PA; UCLA David Geffen School of Medicine, Los Angelas, CA; Georgetown University, Washington, DC; University of California San Diego Health System, San Diego, CA; Memorial Sloan Kettering Cancer Center, Philadelphia, PA.
P2-07-05 Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer
Abu-Khalaf M, Hatzis C, Hodge KA, Baldelli E, Sikov W, Mita M, Valdes-Albini F, Dunetz B, Petricoin E, and Pierobon M. Sidney Kimmel Cancer Center at Jefferson Health, Thomas Jefferson University, Philadelphia, PA; Bristol Myers Squibb, Cambridge, MA; George Mason University, Manassas, VA; Women and Infants Hospital of Rhode Island-Brown University, Providence, RI; Cedar Sinai, Los Angeles, CA; University of Miami, Miami, FL; Side Out Foundation, Fairfax, VA.
P2-07-06 Peripheral T-lymphocytes senescence and response to neoadjuvant therapy (NAT) in operable breast cancer (BC)
Martini V, Saggia C, D'Avanzo F, Rossi V, Dodaro I, Gallarotti E, Pretato T, Varughese FM, Vachanaram AR, Cavalleri M, Stella A, Gobbato S, Tassone A, Gambaro A, Branni C, Maggiora PM, Rua A, Boldorini R, Ferrara E, Krengli M, Gennari A. Division of Oncology, AOU Maggiore, Novara, Italy; Azienda Ospedaliero Universitaria "Maggiore della Carità" Novara, Novara, Italy; University of Piemonte Orientale, Novara, Italy.
P2-07-07 Does OncotypeDX have predictive value in HER2+ breast cancer?
Bilani N, Yaghi M, Saravia D, Jabbal I, Bou Zerdan M, Elson L, Liang H, Nahleh Z. Icahn School of Medicine, Mount Sinai Morningside and West, New York, NY; Cleveland Clinic Florida, Weston, FL.
P2-07-08 Identification of UGT2B15 as a potential biomarker in response to neoadjuvant therapy in HER2+ breast cancer
Gil-Torralvo A, Benavent M, Dominguez-Cejudo MA, Falcon A, Vieites B, Molina-Pinela S, Ruiz M, Montaño Á, Gónzalez R, Martínez J, de la Haba J, Rodríguez A, Queipo MI, Jímenez B, Salvador-Bofill J. Oncology Department. Hospital Universitario Virgen del Rocío Sevilla. Instituto de BioMedicina de Sevilla (IBIS). Alianza Mixta Roche-Andalucia., Seville, Spain; Pathology Department. Hospital Universitario Virgen del Rocío Sevilla. Instituto de BioMedicina de Sevilla (IBIS). Alianza Mixta Roche-Andalucia., Seville, Spain; Oncology Department Hospital Reina Sofía Córdoba. Instituto Maimónides de Investigación Biomédica de Córdoba (Imibic). Alianza Mixta Roche-Andalucía., Seville, Spain; Oncology Department Hospital Clínico Málaga. Alianza Mixta Roche-Andalucía, Málaga, Spain.
P2-07-09 Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer
Kearney MR, Vanguri R, Wang Q, Fenn K, Guo H, Marks D, Hibshoosh H, Kalinsky KM, Connolly E. NYP-Columbia University Medical Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Trumbull, CT; New York University, New York, NY; Winship Cancer Institute at Emory University, Atlanta, GA.
P2-07-10 Germline BRCA screening for locally advanced breast cancer treated by neoadjuvant chemotherapy : defining a subgroup with high rate of mutation and local relapses
Sevenet N, Tunon de Lara C, Leroux J, Bonnet F, Debled M, Lafon D, Barouk-Simonet E, Fournier M, Petit A, Bubien V, Quenel-Tueux N, Brouste V, MacGrogan G. Institut Bergonie, Bordeaux, France.
P2-07-11 Application of the genetic signature MammaPrint™ in the Brazilian population - Real-world study (AGEMA-BRA)
Mansani FP, Freitas-Junior R. Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil; Universidade Federal de Goiás, Goiania, Brazil.
P2-07-12 Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial
Dugo M, Huang C-S, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Anton A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly C, Mariani G, Del Mastro L, Valagussa P, Viale G, Callari M, Gianni L, Bianchini G. IRCCS Ospedale San Raffaele, Milan, Italy; Breast Center, National Taiwan University Hospital, Taiwan, Taiwan; Medical University of Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario de Valencia, Valencia, Spain; IRCCS Azienda ospedaliero Universitaria di Bologna, Bologna, Italy; Oncocyte Corporation, Nashville, TN; AGAPLESION Markus Krankenhaus, Frankfurt am Main, Germany; University Hospital Miguel Servet, Zaragoza, Spain; Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; and Cancer Cluster Salzburg, Salzburg, Austria; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Semmelweis University, Budapest, Hungary; Istituto Europeo di Oncologia, Milan, Italy; Mater Misericordiae University Hospital, Dublin, Ireland; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Italy; Fondazione Michelangelo, Milan, Italy.
P2-07-13 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
Guerriero JL, Baker GJ, Lin J-R, Chen Y-A, Pastorello R, Vallius T, Davis J, Yapp C, Church SE, Miller E, Färkkilä A, Vinayak S, Telli ML, Fulci G, D'Andrea A, Shapiro GI, Tolaney SM, Santagata S, Sorger PK, Mittendorf EA. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA; Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, MA; Department of Pathology, Hospital Sírio Libanês, Sao Paulo, Brazil; Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, MA; Nanostring Technologies, Seattle, WA; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland; University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, Seattle, WA; Stanford University School of Medicine, Palo Alto, CA; GlaxoSmithKline, Waltham, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pathology, Brigham and Women’s Hospital, Boston, MA.
   
  Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive Biomarkers-Other
P2-08-01 Validation of a 16-gene genomic signature to identify early-stage invasive breast cancer patients who may omit radiotherapy
Fyles A, Chang SL, Rey-McIntyre K, Shi W, Feng F, Speers C, Pierce L, McCready D, Liu F-F. Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada; Exact Sciences, Madison, WI; University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI.
P2-08-02 Virtual replication of the NeoSphere trial using SimBioSys TumorScope: Associating standard of care data with clinical outcomes in HER2 positive breast cancer patients to garnish novel insights in silico
Pfeiffer JR, Foley T, Braun E, Antony A. SimBioSys, Inc, Champaign, IL; Rush University Medical Center, Chicago, IL.
P2-08-03 PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer
Blenman KRM, Harigopal M, Huang R, Reisenbichler E, Qing T, Ibrahim E, Singh K, Ramkissoon S, Mustimbo R, Ross J, Pusztai L. Yale University, New Haven, CT; Foundation Medicine, Inc., Cambridge, MA; Brown University, Providence, RI; Bristol Myers Squibb, Princeton, NJ.
P2-08-04 Progressive metastatic breast cancer with no detectable circulating tumor DNA: Evaluating limitations of this highly sensitive tool
Shah AN, Gerratana L, Chandra S, Mukhija D, Katam N, Kang AK, Davis AA, Srivastava M, Jacob S, D'Amico P, Zhang Q, Reduzzi C, Gurley M, Wehbe F, Gradishar WJ, Behdad A, Cristofanilli M. Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Washington University, St. Louis, MO; University of California San Francisco, San Francisco, CA.
P2-08-05 Plasma lipidomics analysis to identify potential non-invasive biomarkers for breast white adipose  inflammation and aromatase expression levels
Cai X, Wei S, Xu Z, Zhou XK, Peck A, Lai S, Isaac G, Olivos H, Munjoma N, Dhungana S, Plumb R, Dannenberg AJ, Iyengar NM. Weill Cornell Medicine, New York, NY; Waters Corporation, Milford, MA; Retired, Pauling, NY; Memorial Sloan Kettering, New York, NY.
P2-08-06 Defining transcriptomic profiles of breast cancer with early lymph node metastases: A FLEX database sub-study
Budhathoki N, Fa'ak F, D'Abreo N, Dhage S, Soe PP, Holmes D, Haan J, Wang S, Dauer P, Menicucci A, Audeh W, Marks DK. June Nylen Cancer Center, Sioux City, IA; Perlmutter Cancer Center at NYU Langone Health, Mineola, NY; Providence Santa Monica, Santa Monica, CA; Agendia, NV, Amsterdam, Netherlands5Agendia, Inc., Irvine, CA.
P2-08-07 Predicting DCIS prognosis using infrared and raman spectroscopy of breast calcifications and soft-tissue microstructure
Nallala J, Calabrese D, Gosling S, Hall A, Pinder S, Bouybayoune I, King L, Marks J, Lips E, Lynch T, Pinto D, Wesseling J, Hwang S, Rogers K, Stone N, on behalf of the Grand Challenge PRECISION consortium. University of Exeter, Exeter, United Kingdom; Cranfield University, Cranfield, United Kingdom; Duke University School of Medicine, Durham, NC; Kings College London, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; www.DCIS411.com, San Diego, CA.
P2-08-08 Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
Sammons S, Elliott A, Force J, Chumsri S, Anders C, Tan AR, Magee D, Zeng J, Korn WM, Kahsraw M, Roussos Torres ET. Duke University, Durham, NC; Caris Life Sciences, Houston, TX; Mayo Clinic, Jacksonville, FL; Levine Cancer Institute/ Atrium Health, Charlotte, NC; University of Southern California, Keck School of Medicine, San Diego, CA.
P2-08-09 Investigation of autoantibodies (AAbs) in HER2+ breast cancer (BC) patients treated in the neo-adjuvant setting
Collins DM, Qiu J, Blayney J, McCabe N, Kennedy R, LaBaer J, Crown J. Dublin City University, Dublin, Ireland; Arizona State University, Tempe, AZ; Queen's University Belfast, Belfast, United Kingdom; Saint Vincent's University Hospital, Dublin, Ireland.
P2-08-10 First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer
Vethencourt A, Trinidad EM, Petit A, Soler-Monsó MT, Gómez Aleza C, Urruticochea A, García-Tejedor A, Gumà Martinez A, Obadia V, Vazquez S, Villanueva R, Fernánez A, Cejuela M, Recalde Penabad S, Stradella A, Gil-Gil M, Pernas S, Gonzalez-Suarez E, Falo C. Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Institut d’Investigacio Biomédica de Bellvitge (IDIBELL-ONCOBELL), L’Hospitalet De Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge and Institut Català d'Oncologia., L'Hospitalet de Llobregat, Barcelona, Spain; Institut d’Investigacio Biomédica de Bellvitge (IDIBELL-ONCOBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Onkologikoa, Donostia, Spain6Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain.
P2-08-11 How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer
Saghir H, Veerla S, Malmberg M, Rydén L, Ehinger A, Saal L, Vallon-Christersson J, Borg Å, Hegardt C, Hedenfalk I, Dieroff-Hay S, Larsson C, Loman N, Kimbung S. Division of Oncology, Dept. of Clinical Sciences, Lund University, Lund, Sweden; Dept. of Hematology, Oncology and Radiation Physics, Lund University Hospital, Lund, Sweden; Bröstcancerförbundet, Stockholm, Sweden; Division of Translational Cancer Research, Dept. of Laboratory Medicine, Lund University, Lund, Sweden.
P2-08-12 Interim analysis of the PREDICT Registry: Changes in treatment recommendation for a biologic signature predictive of radiation therapy (RT) benefit in patients with DCIS
Shivers SC, Whitworth PW, Patel R, Bremer T, Cox CE. PreludeDx, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Good Samaritan Cancer Center, Los Gatos, CA; University of South Florida, Tampa, FL.
P2-08-13 The prognostic significance of Ki67 and progesterone receptor; could they really have prognostic importance in early breast cancer with estrogen receptor positive, HER-2 negative?
Choi SB, Park JM, Ahn JH, Go J, Kim J, Park HS, Kim SI, Park B-W, Park S. Yonsei University College of Medicine, Seoul, Republic of Korea.
P2-08-14 Effect of markers of systemic inflammation on tumor infiltrating lymphocytes in patients with non-metastatic triple negative and HER2+ breast cancer: A single center retrospective study
Chen N, Bulsara S, Hilsenbeck S, Hoyos V. Baylor College of Medicine, Houston, TX.
P2-08-15 Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer
Mohamed MA, Wang C, Buckley M, Lehman J, Canzoniero J, Gocke CD, Nunes R, Park BH, Smith KL, Tao1 J, Tukachinsky H, Wilkinson M, Wolff AC, Stearns V, Santa-Maria CA. Johns Hopkins University School of Medicine, Baltimore, MD; Vanderbilt University Medical Center, Nashville, TN; Foundation Medicine, Cambridge, MA.
P2-08-16 The cross-talk between nuclear p-ser294-FOXO3a and cytoplasmic MMP-2 in breast cancer survival and treatment response
Hou M-F, Yang S-F, Huang Y-C, Chen F-M, Yeh Y-T. Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Fooyin University, Kaohsiung, Taiwan.
P2-08-17 Withdrawn
P2-08-18 Evaluation of the activity of key actionable oncogenic driving pathways in triple negative breast cancer using OncoSignal™; a novel molecular assay based on transcriptional profile analysis
Magliocco G, den Biezen E, Keizer D, Akse M, van Zelst M, van Strijp D, Vermeer S, van de Stolpe A, Magliocco A. Boston University School of Medicine, Boston, MA; Philips Molecular Pathway Diagnostics, Eindhoven, Netherlands; Protean BioDiagnostics Inc, Orlando, FL.
P2-08-19 Prognostic significance of Hounsfield unit of tumor in patients with breast cancer
Kim K, Cho I-J, Noh H, Choi H, Hahn S, Lim ST, Lee J-I, Han A. Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; Department of Radiology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Republic of Korea; Department of Oncology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
P2-08-20 Risk of everolimus- and alpelisib-induced hyperglycemia in obese and non-obese breast cancer patients with or without pre-existing hyperglycemia
Xu B, Messiner T, Williams C. Avera Cancer Institute, Sioux Falls, SD.
P2-08-21 Overall survival associated with BRCA or ATM mutation status in patients with metastatic triple-negative breast cancer: findings from the PRIOR-2 study
Adeboyeje G, Sierra M, Bartels A, Field M, Jhamb S, Buikema A, Joo S. Merck & Co., Inc, Kenilworth, NJ; Optum, Eden Prairie, MN;3Merck & Co., Inc, North Wales, PA.
P2-08-22 Correlation of ER (ESR1), PR (PGR), and HER2 (ERBB2) at protein and mRNA levels in operable breast cancer
Lei L, Wang X, Cheng SH-C. Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
P2-08-23 Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC)
Vos H, Lambein K, Richard F, Nevelsteen I, Bassez A, Lambrechts D, Punie K, Wildiers H, Floris G, Desmedt C, Smeets A. Surgical Oncology, University Hospitals Leuven/KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium; General Medical Oncology, Laboratory of Experimental Oncology, University Hospitals Leuven/KU Leuven, Leuven, Belgium; Pathology, Translational Cell & Tissue Research, University Hospitals Leuven/KU Leuven, Leuven, Belgium.
   
  Epidemiology, Risk, and Prevention: Familial Breast Cancer - Genetic Testing
P2-09-01 Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes
Yadav S, Hu C, Boddicker NJ, Polley E, Hart S, Gnanaolivu R, Na J, Huang H, Yao S, Vachon CM, Teras L, Taylor JA, Sandler DP, Palmer JR, Olson JE, Neuhausen S, Martinez E, Lindstroem S, Le Marchand L, Kooperberg C, Haiman C, Gaudet MM, Lacey JV, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Weitzel JN, Kraft P, Goldgar DE, Nathanson KL, Domchek SM, Couch FJ, CARRIERS Consortium. Mayo Clinic, Rochester, MN; Harvard University T.H. Chan School of Public Health, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; American Cancer Society, Atlanta, GA; NIEHS, Durham, NC; Slone Epidemiology Center at Boston University, Boston, MA; Beckman Research Institute of City of Hope, Duarte, CA; University of California San Diego, San Diego, CA; University of Washington, Seattle, WA; University of Hawaii Cancer Center, Honolulu, HI; Fred Hutchinson Cancer Research Center, Seattle, WA; Keck School of Medicine, University of Southern California, Los Angeles, CA; UWM Joseph J. Zilber School of Public Health, Milwaukee, WI; University of Utah, Salt Lake City, UT; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
P2-09-02 Withdrawn
P2-09-03 Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden
Bychkovsky BL, Lo M-T, Yussuf A, Horton C, Hemyari P, LaDuca H, Garber JE, Rana HQ. Dana-Farber Cancer Institute, Boston, MA; Ambry Genetics, Aliso Viejo, CA.
P2-09-04 Timing and acceptance of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers enrolled in an integrated community-based health care system
Kwan KW, Morton SW, Chung J. Kaiser Permanente Southern California, Department of Hematology/Oncology, Los Angeles, CA; Kaiser Permanente Southern California, Department of Genetics, Los Angeles, CA; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
P2-09-05 Germline BRCA1/2 mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)
Niyazov A, Izano M, Johanson C, Walters S, Berry A, Arondekar B, Laird AD, Shahied Arruda L, Kaplan H. Pfizer Inc, New York, NY; Syapse, San Francisco, CA; Pfizer Inc, Collegeville, PA; Pfizer Inc, La Jolla, CA; Swedish Cancer Institute, Seattle, WA.
P2-09-06 Increased rates of genetic variants of unknown significance in Latino and African American populations of south Texas
Soewito S, Wyatt R, Berenson E, Poullard N, Gessay S, Mette L, Shelby K, Alvarez E, Aviles C, Pulido Saldivar AM, Otto P, Jatoi I, Kaklamani V, Tomlinson GE. University of Incarnate Word, San Antonio, TX; UT Health San Antonio, San Antonio, TX.
P2-09-07 Withdrawn
P2-09-08 Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study
Whitaker K, Parikh R, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Niyazov A, Obeid E. Fox Chase Cancer Center, Philadelphia, PA; RTI Health Solutions, Research Triangle Park, NC; Pfizer Inc, Collegeville, PA;4Pfizer Inc, New York, NY.
P2-09-09 Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience
Higashiyama N, Bulsara S, Hilsenbeck S, Tran T, Brown R, Fang M, Sullivan C, Garza G, Nemati Shafaee M, Osborne CK, Rimawi M, Nangia J. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
P2-09-10 Different CNVs account for 10.4% of pathogenic variants in 1418 patients referred for hereditary breast cancer testing
Tsoulos N, Agiannitopoulos K, Pepe G, Papadopoulou E, Tsaousis GN, Apostolopoulou D, Meintani A, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Christodoulou C, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Kabletsas E, Psyrri A, Giassas S, Ziogas D, Lalla E, Koumarianou A, Papadimitriou C, Ozmen V, Tansan S, Kaban K, Ozatlı T, Tudor Eniu D, Chiorean A, Blidaru A, Nasioulas G. Genekor Medical S.A, Athens, Greece; Metropolitan Hospital, Athens, Greece; Athens Medical Center, Athens, Greece; Theagenio Anticancer Hospital, Thessaloniki, Greece; IASO, General Maternity and Gynecology Clinic, Athens, Greece; Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece; Euromedica General Clinic, Thessaloniki, Greece; Metropolitan General Hospital, Athens, Greece; University Hospital of Ioannina, Ioannina, Greece; Attikon University Hospital, Athens, Greece; General Hospital of Athens "LAIKO", Athens, Greece; Alexandra Regional General Hospital, Athens, Greece; Faculty of Medicine, Istanbul University, Istanbul, Turkey; Tansan Oncology, Istanbul, Turkey; American Hospital, Istanbul, Turkey; Istinye University Hospital, Istanbul, Turkey; Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania; Medimages, Cluj, Romania; Institutul Oncologic Bucuresti, Bucuresti, Romania.
P2-09-11 Uptake of risk-reducing strategies and related challenges among carriers of breast cancer-associated germline pathogenic variants in Mexico
Mesa-Chavez F, Chavarri-Guerra Y, Aguilar y Mendez D, Becerril-Gaitan A, Vaca-Cartagena BF, Santiesteban SG, Aranda-Gutierrez A, Obregon-Leal D, Miaja-Avila M, Ochoa Chavez MF, Rodriguez-Faure A, Franco Jimenez HJ, Weitzel JN, Villarreal-Garza C. Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico; Instituto Nacional de Rehabilitación, Mexico City, Mexico; Latin-American School of Oncology, Duarte, CA.
P2-09-12 Optimizing genetic testing in hispanic women with breast cancer
Garcia AL, Akula N, Kade Derrick D, Worrell CM, Lakhotia S, Menon S, Lathrop K. UT Health San Antonio, San Antonio, TX.
P2-09-13 Is there a male breast cancer cluster region in the BRCA2 gene?
Simões P, Duarte T, Parreira J, Luís A, Bento S, Fragoso S, Santos S, Vaz F, André S. Hospital Beatriz Ângelo, Loures, Portugal; Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
P2-09-14 Characteristics of TNBC patients carrying other than BRCA gene mutations
Cortesi L, Venturelli M, Toss A, Piombino C, Barbieri E, Razzaboni E, Moscetti L, Piacentini F, Omarini C, Domati F, Dominici M. Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
P2-09-15 Frequency of germline mutations in breast cancer susceptibility genes among women under age 50 presenting with parity associated breast cancer
Wrubel E, Dennis SR, Tsukioki T, Sciaraffa T, Luo Y, Khan SA. Northwestern University Feinberg School of Medicine, Division of Breast Surgery, Chicago, IL; Northwestern University Feinberg School of Medicine, Division of Preventive Medicine, Chicago, IL; Northwestern Memorial Hospital, Department of Obstetrics and Gynecology, Division of Clinical Genetics, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
P2-09-16 Clinicopatological features and outcome of breast cancer in CHEK2 germline mutation carriers
Schlosser S, Bernstein Molho R, Karminsky N, Barsuk D, Goldberg Y, Friedman E, Yerushalmi R, Drumea K, Kedar I, Jiveliouk I, Ben David MA. Oncology Institute, Assuta Medical Center, Tel Aviv, Israel; Breast Cancer Unit, Oncology Institute, Sheba Medical Center, Ramat Gan, Israel; Oncology Institute, Wolfson Medical Center, Holon, Israel; Breast Surgery Unit, Assuta Medical Center, Tel Aviv, Israel; Genetics Institute, Rabin Medical Center, Petach Tikva, Israel; Oncogenetic Unit, Sheba Medical Center, Ramat Gan, Israel; Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel; Oncology Institute, Assuta Medical Center, Haifa, Israel.
P2-09-17 Family communication and attitude of patients with breast cancer toward positive pathogenic BRCA1 or BRCA2 mutations. A regional perspective
Mustafa R, Ammar K, Damsees R, El-Atrash M, Bater R, Almasri S, Tamimi F, Abujamous L, Abdel-Razeq H. King Hussein Cancer Center, Amman, Jordan.
P2-09-18 Use of navigators to identify breast cancer patients for genetic counseling and testing: A quality improvement project
Cohen SA, Nixon D. Ascension St. Vincent, Indianapolis, IN.
P2-09-19 Inequitable access to genetic testing leads to missed screening and prevention opportunities for individuals at risk for hereditary breast and ovarian cancer
Pilarski RT, Noble S, Hoang L, Hew R, Gandomi S, LaDuca H, Dolinsky J. Ambry Genetics, Aliso Viejo, CA.
   
  Epidemiology, Risk, and Prevention: Risk Factors and Modeling
P2-10-01 Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with triple-negative breast cancer
Leone JP, Graham N, Leone J, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Vallejo CT, Winer EP, Lin NU, Tayob N. Dana-Farber Cancer Institute, Boston, MA; Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.
P2-10-02 Random periareolar fine-needle aspiration (RPFNA) cell number, prior precancerous breast disease and subsequent uptake of a prevention intervention predict short-term breast cancer risk
Hensing WL, Fabian CJ, Zalles CM, Sharma P, Kreutzjans AL, Powers KR, Chollet-Hilton L, Kimler BF. Department of Medicine, Washington University School of Medicine, Saint Louis, MO; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS; Department of Pathology, Boca Raton Hospital, Boca Raton, FL; Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS.
P2-10-03 Improving breast cancer risk prediction using a convolutional neural network-based mammographic evaluation in combination with clinical risk factors
Michel A, Ro V, McGuinness JE, Mutasa S, Ha R, Crew KD. NYP/Columbia University Irving Medical Center, New York, NY; University of California, Irvine, CA.
P2-10-04 Breast cancer risk assessment tool (BCRAT) predicted breast cancer incidence and breast cancer mortality in the women's health initiative
Nelson R, Pan K, Chlebowski R, Rohan TE, Mortimer J, Wactawski-Wende J, Lane D; Kruper L. City of Hope National Medical Center, Duarte, CA; The Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA; Albert Einstein College of Medicine, Bronx, NY; University of Buffalo, Buffalo, NY; Stony Brook University, Stony Brook, NY. .
P2-10-05 The estimated impact of COVID-19 on population breast cancer screening outcomes, and options for risk-based recovery
Procopio P, Deij S, Velentzis LS, Tattam A, Petelin L, Nickson C. University of Sydney, Woolloomooloo, Australia.
P2-10-06 Validation of abridged breast cancer risk assessment model for the general population
Spaeth E, Dite G, Allman R. Phenogen Sciences, Charlotte, NC; Genetic Technologies Inc, Fitzroy, Australia.
P2-10-07 Prediction of menstruation recovery timing in premenopausal breast cancer patients taking tamoxifen after chemotherapy: An ASTRRA substudy
Lee YJ, Noh WC, Nam SJ, Park B-W, Lee ES, Im SA, Jung YS, Yoon JH, Kang SS, Park KH, Lee S-J, Lee MH, Jeong J, Kim SY, Kim H-A, Han S-H, Han W, Hur MH, Kim S, Ahn S-h Kim HJ. Seoul St. Mary's Hostital, Seoul, Republic of Korea; Korea Cancer Center Hospital, Seoul, Republic of Korea; Samsung Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Ajou University School of Medicine, Suwon, Republic of Korea; Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea; Cha Ilsan Medical Center, Goyang, Republic of Korea; Korea University Anam Hospital, Seoul, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; SoonChunHyang University College of Medicine, Seoul, Republic of Korea; Gangnam Severance Hospital, Seoul, Republic of Korea; SoonChunHyang Univesity College of Medicine, Cheonan Hospital, Cheonan, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea.
P2-10-08 Assessment of risk factors for HER2+ breast cancer recurrence: A literature review
O'Shaughnessy J, Gradishar W, O’Regan R, Gadi V. Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Northwestern University, Chicago, IL; University of Rochester, Rochester, NY; Department of Medicine, University of Illinois at Chicago, Translational Oncology, University of Illinois at Chicago Cancer Center, Chicago, IL.
P2-10-09 Oxysterol profiling in breast adipose tissue identifies brassicasterol and 24-hydroxycholesterol as breast cancer risk predictors
Chen I-C, Kuo W-H, Hu F-C, Wang M-Y, Lu Y-S, Lütjohann D, Lin C-H. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan; International-Harvard Statistical Consulting Company, Taipei, Taiwan; Department of Surgery, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University University, Taipei, Taiwan; 3 Institut fu¨r Klinische Chemie und Klinische Pharmakologie, Universitaetsklinikum Bonnn, Bonn, Germany.
P2-10-10 The associations between brain metastasis and tumor size, nodal status, and patterns of extracranial metastasis vary by subtypes in breast cancer patients: a population-based study
Shen B, Li J, Yang M, Zhang J, Li W, Wang K. Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
   
  Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention - Other
P2-11-01 Breast cancer (BC) risk among patients with benign breast disease (BBD) by NSAID use
Vierkant RA, Masters M, Teras LR, Sherman ME. Mayo Clinic, Rochester, MN; American Cancer Society, Kennesaw, GA; Mayo Clinic, Jacksonville, FL. .
P2-11-02 Subsequent breast cancer among women with HER2+ disease in a large integrated healthcare system
Haque R, Chen LH, Kwan K, Oestreicher N, Chlebowski RT, Lalla D. Kaiser Permanente Southern California, Pasadena, CA; PUMA Biotechnology, Los Angeles, CA.
P2-11-03 Menstrual phase classification of benign breast tissue using hormone-regulated gene expression and morphology
Hosseini O, Helenowski I, Lee O, Zhang H, Wang J, Blanco L, Khan SA. Northwestern University Feinberg School of Medicine, Chicago, IL.
P2-11-04 Participation in a breast cancer prevention clinic before and after implementation of the Affordable Care Act
Tinglin J, Crouse A, Krontiras H. University of Alabama School of Medicine, Birmingham, AL.
P2-11-05 Generating real-world external comparators for randomized clinical trials (RCTs) in metastatic breast cancer (mBC) using electronic health records (EHRs)
Amiri-Kordestani L, Gao X, Baxi S, Bloomquist E, Bryan J, Howie L, Keane C, Kluetz PG, Osgood C, Paliwal P, Rivera DR, Roose J, Schneider J, Singh H, Tang S, Zhang L, Beaver JA. FDA, Silver Spring, MD; Flatiron Health Inc., New York, NY.
P2-11-06 Differential gene expression patterns in healthy breast tissue exhibiting epigenetic age acceleration
Sehl ME, Guo W, Farrell C, Marino N, Henry JE, Storniolo AM, Papp J, Li JJ, Pellegrini M, Horvath S, Ganz PA. UCLA David Geffen School of Medicine, Los Angeles, CA.
P2-11-07 Mammographic density is associated with increased risk of contralateral breast cancers but not of ipsilateral breast tumor recurrences
Cheun JH, Kim H-K, Lee H-B, Han W, Moon H-G. Seoul National University Hospital, Seoul, Republic of Korea.
P2-11-08 Impact of COVID-19 on patients undergoing neoadjuvant therapy: A pre/post pandemic analysis and assessment of quality of care delivered
Corke L, Hajjaj O, Willemsma K, Chia S, Simmons C. BC Cancer, Vancouver, BC, Canada.
P2-11-09 Comparing the effects of various beta blockers on cardiovascular-related mortality in breast cancer patients
Chikermane SG, Gopinathan S, Abdulkareem NM, Johnson ML, Trivedi MV. University of Houston, Houston, TX.
P2-11-10 Heterogeneity of preneoplastic breast tissues drives efficacy of therapeutic agents
Bhardwaj A, Rojo R, Ju Z, Wang J, Bedrosian I. UT MD Anderson Cancer Center, Houston, TX; University of the Philippines Manila, Manila, Philippine.
P2-11-11 Impact of baseline body mass index (BMI) and weight changes after diagnosis in young women with early breast cancer (BC): A multicenter retrospective study
Franzoi MA, Punie K, Laenen A, Dullens B, Fernandes Costa C, Neven P, Wildiers H, Lambertini M, de Azambuja E. Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Centre for Biostatistics and Statistical Bioinformatics, KU Leuven, University of Leuven, Leuven, Belgium; Université Libre de Bruxelles (U.L.B), Brussels, Belgium; IRCCS Policlinico San Martino, Genoa, Italy.
P2-11-12 Benign breast disease and breast malignancy
Ter-Minassian M, Somasundaram B, Visvanathan K. Kaiser Permanente Mid-Atlantic States, Rockville, MD; Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD.
P2-11-13 Distinctive clinicopathological features of premenopausal women with intermediate 21-gene recurrence score
Park JM, Ahn JH, Choi SB, Ko J, Kim JY, Park HS, Kim SI, Park B-W, Park S. Yonsei University College of Medicine, Seoul, Republic of Korea.
P2-11-14 Pathology AI features and immune biomarkers of postpartum involution: Implications for postpartum breast cancer
Ogony JW, De Bel T, Radisky D, VanderLaak J, Sherman M. Mayo Clinic, Jacksonville, FL; Radboud University, Nijmegen, Netherlands.
P2-11-15 Clinical trial enrollment for initial therapy of breast cancer: Exploring factors associated with poor accrual and significant disparities
Advani PP, Spaulding A, Hochwald A, Baksh M, Hodge D, Chumsri S, Monestime S, Ailawadhi S. Mayo Clinic, Jacksonville, FL.
P2-11-16 Rate of breast biopsy referrals in BRCA mutation carriers: A retrospective comparative study and matched analysis
Pomerantz A, Tsoref D, Grubstein A, Wadhawker S, Rapson Y, Gadiel I, Goldvaser H, Hammerman A, Shochat T, Sharon E, Yerushalmi R. Institute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Petah Tikva, Israel; Radiology Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Surgery Department, Breast Cancer Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Chief Physician's Office, Clalit Health Services Headquarters, Tel Aviv, Israel; Statistical Consulting Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
P2-11-17 Feasibility of microbiome analysis from random periareolar fine needle aspiration in premenopausal women at increased risk for breast cancer
Nye LE, Klemp JR, Powers KR, O'Dea AP, Kreutzjans AL, Metheny T, Phillips TA, Carlson SE, Kimler BF, Fabian CJ. University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS.
P2-11-18 Weekly evaluation of α estrogen and progesterone receptors in women´s breast epithelium after oral combined hormonal contraceptive use for one month
Araujo Neto JT, Nazário ACP, Taniguchi CK, Berrettini Jr, A, Fenile R. Federal University of Sao Paulo, São Paulo, Brazil.
P2-11-19 Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC)
Veenstra DL, Hendrix N, Dolan CM, Fisher KA, Lalla D, Oestreicher N, Brufsky A. University of Washington, Seattle, WA; T.H. Chan School of Public Health, Harvard University, Boston, MA; CMD Consulting, Sandy, UT; Puma Biotechnology Inc., Los Angeles, CA; Puma Biotechnology Inc., University of California San Francisco, San Francisco, CA; Magee-Womens Hospital of UPMC, Pittsburgh, PA.
P2-11-20 A risk tool for digital breast tomosynthesis to predict breast cancer and guide clinical follow-up
Eriksson M, Destounis S, Schilling K. Karolinska Institutet, Stockholm, Sweden; Elisabet Wende Breast Care, Rochester, NY; Boca Raton Regional Hospital, Boca Raton, FL.
P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model
Hughes E, Bernhisel R, Pederson H, Probst B, Simmons T, Wagner S, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Gordon OK, Klemp J, Mukherjee S, Offit K, Olopade F, Vijai J, Weitzel J, Whitworth P, Yehia L, Kurian A, Robson M, Slavin TP, Gutin A, Lanchbury JS. Myriad Genetics, Inc., Salt Lake City, UT; Cleveland Clinic, Cleveland, OH; University of Pennsylvania School of Medicine, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Grand View Health, Sellersville, PA; Providence Health, Burbank, CA; University of Kansas Cancer Center, Westwood, KS; Memorial Sloan Kettering Cancer Center, New York, NY; University of Chicago, Chicago, IL; Latin American School of Oncology, Sierra Madre, CA; Nashville Breast Center, Nashville, TN; Stanford University School of Medicine, Stanford, CA.
   
  Treatment - Therapeutic Strategies: Neoadjuvant Chemotherapy
P2-12-01 Withdrawn
P2-12-02 Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab
Zhou L, Xu S, Xue X, Zhang Y, Gu B, Lin B, Bai J, Zhang H, Wu K, Lin Y, Ye Y, Du Y, Sheng X, Xu Y, Zhang J, Yin W, Lu J. Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China; Department of Mammary, YueYang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Department of Breast Surgery, Central Hospital of Handan; Breast Center, The Fourth Hospital of Hebei Medical University, Hebei, China; Department of Thyroid and Breast Surgery, Kunshan Second People's Hospital, Jiangsu, China; Department of Thyroid and Breast Gland Surgery, Shenzhen Longgang Central Hospital, Guangdong, China; Department of Thyroid and Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical Collage, Hohhot, China; Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
P2-12-03 Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases
Argyriadis A, Bange M, Mehta K, Loibl S, Khodaverdi S, Braun S, Denkert C, Jackisch C. Breast Cancer Center, Sana Clinic, Offenbach am Main, Germany; Pathology Institute, Sana Clinic, Offenbach am Main, Germany; German Breast Group, Neu-Isenburg, Germany; Department of Pathology, Philipps University, Marburg, Germany.
P2-12-04 Characterization of gut microbiome composition in triple negative breast cancer patients treated with neoadjuvant chemotherapy
Vernaci GM, Massa D, Patuzzi I, Menichetti A, Giarratano T, Griguolo G, Miglietta F, Fassan M, Savarino E, Conte P, Guarneri V, Dieci MV. Medical Oncology 2 Unit, Istituto Oncologico Veneto; Department of Surgery, Oncology and Gastroenterology University of Padova, Padova, Italy; Research & development Division, EuBiome S.r.l., Padova, Italy; Medical Oncology 2 Unit, Istituto Oncologico Veneto, Padova, Italy; Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy; Department of Surgery, Oncology and Gastroenterology University of Padova, Padova, Italy.
P2-12-05 Efficacy of neoadjuvant systemic carboplatin therapy in triple-negative breast cancer
Thomssen C, Schüler K, Bauer M, Reinhardt K, Strauß H-G, Vetter M. Dept. of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; Dept. of Gynecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
P2-12-06 Pathological response-guided postoperative treatment strategy for positive HR/negative HER2 and positive lymphnodes breast cancer patients with non-responsive pathological results to neoadjuvant chemotherapy
Yang Y, Chen X, Fan Z, He Y, Xie Y, Li J, Wang T, Ouyang T. Beijing Cancer Hospital, Beijing, China.
P2-12-07 Fdg PET/CT early response prediction for triple negative breast cancer neoadjuvant chemotherapy with addition of carboplatin
Kubeczko M, Michalik A, Badora-Rybicka A, Polakiewicz-Gilowska A, d'Amico A, Kalemba M, Leśniak A, Świderska K, Mianowska-Malec M, Pasierbek A, Łanoszka B, Chomik K, Bobek-Billewicz B, Jarząb M. Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
P2-12-08 Impact of summation dose intensity product on pathologic response in patients receiving neoadjuvant chemotherapy for early breast cancer
Deutsch TM, Kobel M, Feisst M, Riedel F, Smetanay K, Fremd C, Michel L, Golatta M, Heil J, Wallwiener M, Schneeweiss A. Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
P2-12-09 Correlation between pathologic complete response (pCR), event-free survival (EFS)/ disease-free survival (DFS) and overall survival (OS) in neoadjuvant and/or adjuvant (NAdj/Adj) hormone receptor positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC)
Gogate A, Kim I, Ranjan S, Kumar A, Papademetriou E, Bhandari H, Potluri R. Bristol Myers Squibb, Princeton, NJ; SmartAnalyst India Pvt. Ltd., Gurgaon, India; SmartAnalyst Inc., New York, NY.
P2-12-10 Improving pathological complete response in luminal breast cancer after neoadjuvant chemotherapy
Gasol Cudós A, Morales Murillo S, Rodriguez Galindo A, Pallisé Subirats O, Melé Olivé J, Canosa Morales C, vilardell villellas F, Sanchez Guzman DR, Veas Rodriguez J. Hospital Arnau de Vilanova de Lleida, Lleida, Spain.
P2-12-11 Multi-omics fusion for prediction of response to neoadjuvant therapy in breast cancer with external validation
Li B, Zhu T, Liu Z, Wang K, Tian J. CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China; Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangdong, China.
P2-12-12 The effect of Neoadjuvant Chemotherapy in reducing the need for axillary lymph node dissection in HR+/HER2- node positive breast cancers
Jabbal IS, Saravia D, Yaghi M, Bilani N, Elson L, Liang H, Nahleh Z. Cleveland Clinic Florida, Weston, FL.
P2-12-13 Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
Ji JH, Bae SJ, Kim S-G, Kim MH, Kim G-M, Sohn J, Kim JH, Ahn SG, Jeong J. Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
P2-12-14 Effect of moderate physical exercise on the immune system modulation in breast cancer patients during preoperative chemotherapy: The NEO-RUNNER study
Garrone O, Paccagnella M, Ruatta F, Abbona A, Falletta A, Vanella P, Denaro N, Merlano MC. AO S. Croce e Carle, Cuneo, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
P2-12-15 Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer
Chan N, Lu S-e, Wang Y, Riedlinger GM, Omene C, George M, Malhotra J, Kowzun M, Eladoumikdachi FG, Potdevin LB, Kumar S, Matsuda K, Desai S, Patel N, Toppmeyer DL, Ganesan S, Hirshfield K. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Rutgers School of Public Health- Biostatistics, Piscataway, NJ; Robert Wood Johnson Medical School, New Brunswick, NJ.
P2-12-16 Use of ovarian function suppression to preserve fertility during neoadjuvant chemotherapy oncologically safe in women under age 40: An inverse probability weighting adjusted analysis
Lee YJ, Kim S, Kim HJ. Seoul St. Mary's Hostital, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea.
P2-12-17 Comparative outcomes of Neoadjuvant versus Adjuvant chemotherapy in HR+/HER2- node positive breast cancer
Jabbal IS, Saravia D, Yaghi M, Bilani N, Elson L, Liang H, Nahleh Z. Cleveland Clinic Florida, Weston, FL.
P2-12-18 A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer
Lynce F, Yeh ED, Regan MM, Qin L, Bay CP, Krop I, Harrison BT, Nakhlis F, Bellon J, Overmoyer B. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.
P2-12-19 Platinum is essential in neoadjuvant treatment of triple negative breast cancer: A network meta-analysis
Li J, Chen L, Tan W, Qi F, Zhang Y, Wang Z, Shao Z. Shanghai Cancer Center, Shanghai, China; Nottingham Clinical Trials Unit, Nottingham, United Kingdom; Systematic Review Solutions Ltd, Shanghai, China.
P2-12-22 Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense adriamycin/cyclophosphamide in locally advanced triple negative breast cancer: A single-center real-world experience
Chen N, Bulsara S, Hilsenbeck S, Nangia J. Baylor College of Medicine, Houston, TX.
P2-12-23 Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer
Hirakata T, Yanagita Y, Fujisawa T, Kinoshita T, Horikoshi H, Oya N, Akiyoshi T, Iijima M, Miyamoto T, Yanai K, Matsumoto H, Inoue K, Horii R, Fujii T, Shirabe K. Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Tsurugaya Hospital , Gunma, Japan; Gunma University, Gunma, Japan.
P2-12-24 Exosomal metabolic signatures are associated with differential response to neoadjuvant chemotherapy in patients with breast cancer
Joshi S, Garalapati C, Bhattarai S, Chandrashekar DS, Varambally S, Deep G, Aneja R. Georgia State University, Atlanta, GA; University of Alabama at Birmingham, Alabama, GA; Wake Forest School of Medicine, Winston-Salem, NC.
   
  Treatment - Therapeutic Strategies: HER2-Targeted Therapy
P2-13-01 Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)
Ademuyiwa FO, Northfelt D, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury M, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Ma CX. Washington University, Saint Louis, MO; Mayo Clinic, Phoenix, AZ; Roswell Park Cancer Institute, Buffalo, NY.
P2-13-02 Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis
Weiss A, Waks AG, Laws A, Tolaney SM, Winer EP, Mittendorf EA, Partridge AH, King TA. Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA.
P2-13-03 KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype
Kuemmel S, Gluz O, Reinisch M, Kostara A, Scheffen I, Graeser M, Luedtke-Heckenkamp K, Hartkopf A, Hilpert F, Kentsch A, Ziske C, Depenbusch R, Braun M, Blohmer J, zu Eulenburg C, Christgen M, Bartels S, Kreipe H, Pelz E, Schmid P, Harbeck N. Breast Unit, Clinics Essen-Mitte, Essen, Germany; West German Study Group, Moenchengladbach, Germany; GynOnco Duesseldorf, Duesseldorf, Germany; Niels-Stensen-Kliniken Franziskus-Hospital, Georgsmarienhuette, Germany; University Clinics Tuebingen, Department for Senology, Tuebingen, Germany; Breast Center Hamburg at Hospital Jerusalem, Hamburg, Germany; Diakovere Henriettenstift, Dept. for Gynecology, Hanover, Germany; Praxis Dr. H. Forstbauer, C. Ziske, R. Reihs, E. Rodermann, A. Diel, Troisdorf, Germany; Onkodok GmbH, Guetersloh, Germany; Rotkreuz-Clinics Munich, Munich, Germany; Charité - University Medicine Berlin, Dept. of Gynecology with Breast Center, Berlin, Germany; Hanover Medical School, Institute of Pathology, Hanover, Germany; Institute for Pathology, Viersen, Germany; Queen Mary University of London, London, United Kingdom; Breast Center, Dept. OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany.
P2-13-04 Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer
Pivot X, Pegram MD, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko IM, Dvorkin M, Ahn JH, Im S-A, Litwiniuk M, Shparyk YV, Ho GF, Kislov NV, Wojtukiewicz M, Sarosiek T, Chae YS, Ahn JS, Jang H, Kim S, Lee J, Lee JY, Yoon YC. Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Stanford Women’s Cancer Center, Stanford, CA; Vall d’Hebron Institute of Oncology, Barcelona, Spain; Charité Campus Benjamin Franklin, Berlin, Germany; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Milan, European Institute of Oncology, Milan, Italy; Dnipropetrovsk City Multy-Field Clinical Hospital #4, Dnipropetrovsk, Ukraine; Omsk Region Budgetary Healthcare Institution “Clinical Oncology Dispensary”, Omsk, Russian Federation; Asan Medical Center, Seoul Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Wielkopolskie Centrum Onkologii, Poznan, Poland; Lviv State Oncological Regional Therapeutical and Diagnostic Center, Lviv, Ukraine; University Malaya Medical Centre, Kuala Lumpur, Malaysia; State Budgetary Healthcare Institution of Yaroslavl Region “Regional Clinical Oncology Hospital”, Yaroslavl, Russian Federation; Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie, Bialystok, Poland; Magodent Sp. Z o.o., Warszawa, Poland; Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea; Samsung Medical Center, Seoul, Republic of Korea; Samsung Bioepis, Incheon, Republic of Korea.
P2-13-05 Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)
Lin NU, Lueftner D, Brufsky AM, Tolaney SM, Melisko ME, Holmes FA, Awada A. Dana-Farber Cancer Institute, Boston, MA; University Hospital Charité, Berlin, Germany; Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA; University of California San Francisco, San Francisco, CA; Texas Oncology, US Oncology, Houston, TX; Jules Bordet Institute, Brussels, Belgium.
P2-13-06 Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer
Ferraro E, Safonov A, Wen HY, Brogi E, Gonan M, Barrio AV, Razavi P, Chandarlapaty S, Modi S, Seidman AD, Norton L, Robson ME, Dang CT. Memorial Sloan Kettering Cancer Center, New York, NY.
P2-13-07 Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
Bedard PL, Im S-A, Elimova E, Rha SY, Goodwin R, Ferrario C, Lee K-W, Hanna D, Meric-Bernstam F, Mayordomo J, Beeram M, Hamilton E, Chaves J, Cobleigh M, Mwatha T, Woolery J, Oh D-Y. Princess Margaret Cancer Centre, Toronto, ON, Canada; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; University of Ottawa Cancer Centre, Ottowa, ON, Canada; Jewish General Hospital da, Montréal, QC, Canada; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; USC Norris Comprehensive Cancer Center, Los Angeles, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Colorado Cancer Center, Aurora, CO; The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Northwest Medical Specialists, Tacoma, WA; Rush University Medical Center, Chicago, IL; Zymeworks Inc., Vancouver, BC, Canada.
P2-13-08 Combined peri-operative lapatinib and trastuzumab in early HER2-positive breast cancer - Long term results of the randomized UK EPHOS-B trial
Bundred N, Porta N, Adrian Murray Brunt , Cramer A, Hanby A, Shaaban A, Rakha E, Armstrong A, Cutress R, Dodwell D, Emson M, Evans A, Hartup S, Horgan K, McIntosh S, Naik J, Narayanan S, Oii J, Skene A, Cameron D, Bliss J. Manchester University NHS Foundation Trust, Manchester, United Kingdom; The Institute of Cancer Research, London, United Kingdom; University Hospitals of North Midlands NHS Trust and Keele University, Keele, United Kingdom; The Christie Pathology Partnership, Manchester, United Kingdom; University of Leeds &, Leeds Institute of Medical Research, Leeds, United Kingdom; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Southampton and University Hospital Southampton, Southampton, United Kingdom; University of Oxford, Oxford, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Poole Hospital NHS Foundation Trust, Poole, United Kingdom; St James’s University Hospital, Leeds, United Kingdom; Queen’s University Belfast, Belfast, United Kingdom; Mid Yorkshire NHS Hospitals Trust, Wakefield, United Kingdom; University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom; Royal Bolton Hospital, Bolton, United Kingdom; University of Southampton, Southampton, United Kingdom; University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.
P2-13-09 An investigational next generation ADC (DAN-311) is highly effective in HER2-low breast cancer models
Wright AP, Wyatt EA, Lamm RJ, Blumenfeld CM, Bradley JD, Shrikhande G, Hagerty T. Dantari, Inc., Thousand Oaks, CA.
P2-13-10 First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Fudan University Shanghai Cancer Center, Shanghai, China; Tumor Hospital of Harbin Medical University, Harbin, China; Sun Yat-sen Memorial Hospital, Guangzhou, China; Henan Cancer Hospital, Zhengzhou, China; Zhejiang Cancer Hospital, Hangzhou, China; Precision Scientific (Beijing) Co., Ltd., Beijing, China; Jiangsu Alphamab Biopharmaceuticals Co.,Ltd., Suzhou, China.
P2-13-11 Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns
Lv H, Bai Q-M, Liu Y, Wang Z-H, Shui R-H, Lu H-F, Xu X-L, Yu B-H, Tu X-Y, Bi R, Cheng Y-F, Zhou X-Y, Shao Z-M, Wen-Tao Yang W-T. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
P2-13-12 High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study
Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal M, Corsetto P, Belfiore A, Lorenzini D, Daidone MG, VIngiani A, Pupa SM, Pruneri G, Vernieri C. stituto Nazionale dei Tumori, Milano, Italy; Breast International Group (BIG), Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; Institute Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain; Breast Center Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; Ulm University Hospital, Ulm, Germany; Clinical Trial Department, Eastleigh Breast Care Center, Pretoria, South Africa; University of Milan, Milano, Italy.
P2-13-13 The patient-centered paradox: A US-based survey of physician- and patient-reported experiences with biosimilar trastuzumab
Papautsky EL, Carlson M, Lustberg M. University of Illinois at Chicago, Chicago, IL; Chicago, IL; Yale University, New Haven, CT.
P2-13-14 Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: real-world evidence
Kim JH, Lee JB, Bae SJ, Ahn SG, Jeong J, Kim MH, Kim S-G, Kim GM, Kim JY, Park HS, Park S, Park BW, Kim SI, Sohn J. Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
P2-13-15 Withdrawn
P2-13-16 Dual HER2-blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T. Results from a German non-interventional study (NIS) HELENA (NCT01777958)
Thill M, Grafe A, Klare P, Luedtke-Heckenkamp K, Reichert D, Wimberger P, Zaiss M, Ziegler-Loehr K, Eckl T, Schneeweiss A. Department of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt am Main, Germany; Medical Center Nordhausen gGmbH, Nordhausen, Germany; Gynecological out-patient Clinic, Berlin, Germany; Niels-Stensen-Clinics, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Center for Oncology, Ammerland-Clinic, Westerstede, Germany; Department of Gynecology and Obstetrics TU Dresden, National Center for Tumor Diseases (NCT/UCC), German Cancer Research Center (DKFZ), Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; Practice for Interdisciplinary Oncology & Hematology, Freiburg, Germany; Practice for Gynecological Oncology, Cologne, Germany; Roche Pharma GmbH, Grenzach-Whylen, Germany; National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
P2-13-17 A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin® as neoadjuvant treatment in combination with anthracycline/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer - a multinational phase III study conducted during the COVID-19 pandemic
Grohmann-Izay B, Huang C-S, Dzagnidze G, Llinas N, Misra A, Pominchuk D, Prokhorov A, Rapoport B, Semiglazov V, Tseng L-M, Yanez Ruiz E, Loibl S. EirGenix GmbH, Munich, Germany; National Taiwan University Hospital, Taipei, Taiwan; LTD S. Khechinashvili University Hospital, Tbilisi, Georgia; Clinic Life Foundation, Medellin, Colombia; King George's Medical University, Department of Endocrine Surgery, Shatabdi Phase II, Uttar Pradesh, India; Medical Center "VERUM" Limited Liability Company, Kyiv, Ukraine; Minsk City Clinical Oncology Center, Minsk, Belarus; Medical Oncology Centre of Rosebank, Johannesburg, South Africa; N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russian Federation; Taipei Veterans General Hospital, Taipei, Taiwan; Limited Medical Research Society, Temuco, Chile; GBG Forschungs GmbH, Neu-Isenburg, Germany.
P2-13-18 Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models
Proia T, Wallez Y, Cheraghchi Bashi A, Wilson Z, Randle S, Anderton M, Carroll D, Rasheed Z, Pease JE, Leo E, Mettetal J. AstraZeneca Pharmaceuticals, Gaithersburg, MD.
P2-13-19 Statin modulation of antibody drug conjugate activity in breast cancer models and patients
Drago JZ, Pereira PR, Safonov A, Marra A, Rao Y, Liu B, Ahmed M, Modi S, Reis-Filho J, Robson M, Montemurro F, Razavi P, Lewis JS, Chandarlapaty S. Memorial Sloan Kettering Cancer Center, New York, NY; Washington University St. Louis, St. Louis, MO; Candiolo Cancer Institute, Candiolo, Italy.
P2-13-20 Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
Sang Y, Wu J, Yang B. Fudan University Shanghai Cancer Center, Shanghai, China.
P2-13-21 Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
Holmes FA, Patt D, Manalo Y, Smith JC, Papish SW, Efrat N, Arance A, Zhang B, Lalla D, Wong A, Martin M. Texas Oncology, US Oncology, Houston, TX; Texas Oncology, Austin, TX; Coastal Bend Cancer Center, Corpus Christi, TX; Confluence Health, Wenatchee, WA; Summit Health, Florham Park, NJ; Holy Family Hospital, Nazareth, Israel; Hospital Clinic of Barcelona, Barcelona, Spain; Puma Biotechnology Inc., Los Angeles, CA; Puma Biotechnology Inc., San Francisco, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
P2-13-22 Comparative effectiveness of initiating chemotherapy with or without trastuzumab based regimens as third line treatment for metastatic breast cancer
Sanglier T, Ross R, Shi T, Mouta J, Cardoso F. F.Hoffmann-La Roche, Basel, Switzerland; Genesis Research, Hoboken, NJ; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and ABC Global Alliance, Lisbon, Portugal, Lisbon, Portugal.
P2-13-23 Activity and tolerability of combination of trastuzumab deruxtecan with the pan-AKT inhibitor capivasertib in preclinical HER2+ and HER2-low breast cancer models
Cheraghchi Bashi A, Proia T, Randle S, Anderton M, Rasheed Z, Pease JE, Barry S, Carroll D, Mettetal J. AstraZeneca Pharmaceuticals, Gaithersburg, MD.
P2-13-24 Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer
Kavuri SM, Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki L, Lewis A, Sallas C, Yates C, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis M. Baylor College of Medicine, Houston, TX; Tuskegee University, Tuskegee, AL; University, Tuskegee, Tuskegee, AL.
P2-13-25 A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer
Krop I, Hamilton E, Jung KH, Modi S, Kalinsky KM, Phillips G, Shi R, Monemi S, Mamounas M, Saad O, Choeurng V, Commerford R, Cho E, Ungewickell A, LoRusso P. Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Memorial Sloan Kettering Cancer Center, New York, NY; Winship Cancer Institute, Emory University, Atlanta, GA; Genentech, Inc., South San Francisco, CA; Smilow Cancer Center, Yale University, New Haven, CT.
P2-13-26 Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): first real-life data from the cohort temporary authorization for use (cATU) program in France
Petit T, Hajjaji N, Antoine E-C, Benderra M-A, Gozy M, Foa C, Mouysset J-L, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Lai Tiong F, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga J-Y. Département d’Oncologie Médicale, Centre Paul Strauss, Strasbourg, France; Département de Cancérologie Sénologique, Centre Oscar Lambret, Lille, France; Département d’Oncologie Médicale, Clinique Hartmann, Neuilly-sur-Seine, France; Département d’Oncologie Médicale, Hôpital Tenon, Paris, France; Département de Radiothérapie-Oncologie, Clinique de l’Europe, Amiens, France; Département d’Oncologie Médicale, Hôpital Saint-Joseph, Marseille, France; Département de Cancérologie, Hôpital Privé de Provence, Aix-en-Provence, France; Unité Oncologie Sein-Gynécologie, Institut Sainte-Catherine, Avignon, France; Département d’Oncologie Médicale, CHU Grenoble, Grenoble, France; Département d’Oncologie Médicale, Hôpital Américain de Paris, Neuilly-sur-Seine, France; Département d’Oncologie Médicale, CHU Amiens, Amiens, France; Département d’Oncologie Médicale, Centre Georges François Leclerc, Dijon, France; Département d’Oncologie, Hôpital Privé Le Bois, Lille, France; Département d’Oncologie Médicale, Institut Curie, Paris, France; Département d’Oncologie Médicale, Centre Eugène Marquis, Rennes, France; Département d’Oncologie Médicale, Institut de Cancérologie de l’Ouest, Saint-Herblain, France; Département d’Hémato-oncologie, CHU Sud Réunion, Saint-Pierre, France; Breast Disease Unit, APHP, Hôpital Saint-Louis, Pathophysiology of Breast Cancer Team, Université de Paris, INSERM U976, HIPI, Paris, France; Service d’Oncologie Médicale, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Département d’Oncologie Médicale, Centre François Baclesse, Caen, France; Département d’Oncologie Médicale, Centre Léon Bérard, Lyon, France.
P2-13-27 Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
Loirat D, Logeart J, Vaflard P, Noret A, Saint-Ghislain M, Borcoman E, Hurgon A, Cros C, Genevee T, Bellesoeur A, Ricci F, Lerebours F, Escalup L, Sablin M-P, Bidard F-C, Cottu PH, Pierga J-Y. Institut Curie, Paris, France.
P2-13-28 Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines
O'Reilly D, Gaynor N, Conlon N, Diala I, Eli LD, Crown J, Collins DM. Dublin City University, Dublin, Ireland; Puma Biotechnology Inc, Los Angeles, CA; St Vincents University Hospital, Dublin, Ireland.
P2-13-29 Analysis of GP2 immune response and relationship to recurrence in a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 (GLSI-100) vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
Patel SS, McWilliams DB, Patel MS, Fischette CT, Thompson J, Daugherty FJ. Greenwich LifeSciences, Stafford, TX
P2-13-30 First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib
Lüftner D, Bartsch R, Breitenstein U, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Schwitter M, Zaman K, Wrobel D, Guth D, Terhaag J, Zaiss M, Schinköthe T, Harbeck N. University Hospital Charité, Berlin, Germany; Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria; Division of Oncology, Brust-Zentrum Zurich, Zurich, Switzerland; Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria; Department of Gynecology and Obstetrics, Klinikum Offenbach, Offenbach, Germany; Department of Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Internal Medicine III, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria; University Hospital Mainz, Dept. Gynecology, Mainz, Germany; Kantonsspital Graubünden, Chur, Switzerland; Breast Center, Lausanne University Hospital CHUV, Lausanne, Switzerland; Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Germany; Gyneco-oncological practice Dr. Guth, Plauen, Germany; Rottal/Inn Clinic, Eggenfelden, Germany; Oncology Practice, Freiburg, Germany; CANKADO Service GmbH, Kirchheim, Germany; Breast Center, Dept. OB&GYN, LMU University Hospital, Munich, Germany.
P2-13-31 Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial
Wang X, Huang J, Zheng Y, Shao X, Cao W, Chen Z, Shi Y, Cai L, Chen W, Guo Z, Liu J, Shen P, Chen Y, Wang X, Li H, Li M. Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Department of Internal Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China; Medical Oncology Department 2, The Third Hospital of Nanchang, Nanchang, China; Breast Surgery Department 5, The Third Hospital of Nanchang, Nanchang, China; Department of Breast Cancer, Fujian Medical University Cancer Hospital, Fuzhou, China; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Department of Breast Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China; Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
P2-13-32 Pyrotinib in combination with letrozole for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
Ouyang Q, Xiong H, Yan M, Zhong J, Ran L, Luo T, Liu L, Li J, Yang X, Xiao H, Xie N, Wu H, Gao J, Lu J, Hu X, Hu Z, Tian C, Shui Z, Cao M. Hunan Cancer Hospital, Changsha, China; Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; Henan Cancer Hospital, Zhengzhou, China; The First Affiliated Hospital of Guangxi Medical University, Nanning, China; Guizhou Cancer Hospital, Guiyang, China; West China Hospital, Sichuan University, Chengdu, China.
P2-13-33 Preclinical development of DHES0815A: a HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody
Lewis Phillips G, Li G, Guo J, Yu S-F, Lee G, Zhang D, Dragovich P, Pillow T, Wei B, Lee MV, Saad O, Masih S, Leipold D, Crocker L, Schutten M. Genentech, South San Francisco, CA.
P2-13-34 A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
Rooney A, Sharma P, O'Dea AP, Nye L, Elia M, He J, Fabian C, Khan Q. Kansas University Medical Center, Kansas City, KS.
P2-13-35 Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
Wang Y, Zhao J, Yuan Z, Zou G, Li H, Ding L, Yang Y, ai J, Liu D, Yao H. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Medical Oncology, Guangzhou Panyu Central Hospital, Guangzhou, China; Department of Breast Surgery, the Sixth Affiliated Hospital, Guangzhou, China.
P2-13-36 Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model
Castel ME, Conlon NT, Walsh N, Diala I, Eli L, Crown J, Collins DM. Dublin City University, Dublin, Ireland; Puma Biotechnology, Inc, Los Angeles, CA; Saint Vincent’s University Hospital, Dublin, Ireland.
P2-13-37 A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients
Shao B, Yu Z, Wang Y, Zhao G, Zhou F, Wei R. Mudanjiang Cancer Hospital, Mudanjiang, China; Daqing People's Hospital, Daqing, China; The First Hospital of Qiqihar, Qiqihar, China; Qiqihar Hospital of Traditional Chinese Medicine, Qiqihar, China.
P2-13-38 Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia
Lok SW, De Boer R, Baron-Hay S, Button P, Devitt B, Forster B, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely BE, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P. The Walter and Eliza Hall Institute of Medical Research and Peter MacCallum Cancer Centre, Parkville, VIC, Australia; Peter MacCallum Cancer Centre and St Vincent’s Private Hospital, Melbourne, VIC, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia; OzBiostats Pty. Ltd, Sydney, VIC, Australia; Eastern Health Clinical School, Boxhill, VIC, Australia; The Poche Centre, North Sydney, NSW, Australia; Orange Health Service, Orange, NSW, Australia; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Roche Products, Pty. Limited, Sydney, NSW, Australia; Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia; Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW, Australia; Sydney Adventist Hospital and Sydney University, Wahroonga, NSW, Australia; Royal Hobart Hospital, Hobart, TAS, Australia; Yarra Oncology, Ringwood East, VIC, Australia; Wollongong Private Hospital, Wollongong, NSW, Australia; The Walter and Eliza Hall Institute of Medical Research and Melbourne University, Parkville, VIC, Australia.
P2-13-39 Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models
Mahdi AF, Conlon NT, Eli LD, Diala I, Crown J, Collins D. Dublin City University, Dublin, Ireland; Puma Biotechnology, Inc., Los Angeles, CA; Saint Vincent’s University Hospital, Dublin, Ireland.
P2-13-40 Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study
Li Y, Tong Z, Ouyang Q, Wu X, Li W, Cai L, Yu Z, Han Z, Wang X, Li M, Yang J, Li L, Niu Z, Wang H, Wang Q, Li Y, Teng Y, Zhu S, Xu B. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China; Department of Breast Surgery, Hubei Cancer Hospital, Wuhan, China; Department of Oncology, The First Hospital of Jinlin University, Jilin, China; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China; Department of Breast Surgery, Shandong Cancer Hospital, Shandong Academy of Medical Science, Jinan, China; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital & Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China; Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China; Departments of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; Department of Breast Center, Yuncheng Central Hospital, Yuncheng, China; Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China; Breast Medical Center, Qingdao Central Hospital, Qingdao, China; Breast Center, Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing, China; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Department of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, China.
P2-13-41 First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer
Xie H, Li W, Yao Y, Ni S, Yi T, Cheng J, Fang Q, Zhang L, Zhou J, Wu X, Wang C, Zhang Y, Qin J, Shao Q, Zhao T, Huang X, Xu L. Jiangsu Province Hospital, Nanjing, China; Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China; Affiliated Hospital of Nantong University, Nantong, China; Taizhou People's Hospital, Taizhou, China; The First People's Hospital of Changzhou, Changzhou, China; The First People's Hospital of Lianyungang, Lianyungang, China; Affiliated Hospital of Jiangnan University, Wuxi, China; Yancheng Third People's Hospital, Yancheng, China; Zhongda Hospital Southeast University, Nanjing, China; Jiangyin People's Hospital, Jiangyin, China; Taixing People's Hospital, Taixing, China; Changzhou No.2 People's Hospital, Changzhou, China.
P2-13-42 Withdrawn
P2-13-43 Preclinical and early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer
Zhang J, McAndrew N, Yu W, Pan X, Wang M, Hu X. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Division of Hematology/Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA; Dizal Pharmaceuticals, Shanghai, China.
P2-13-44 HDAC6 is an unfavorable prognostic factor in HER2-positive breast cancer patients treated with adjuvant trastuzumab
Ravaioli S, Maltoni R, Petracci E, Palleschi M, Balzi W, Pirini F, Tumedei MM, Zanoni M, Cortesi M, Martinelli G, Rocca A, Bravaccini S. IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
P2-13-45 Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors
Van Tine BA, Mita M, Barve MA, Hamilton EP, Brenner AJ, Valdes F, Ahn D, Hubbard J, Starr J, Georgy A, Pelham J, Anand BS, Strack T, Machado Sandri A, Wainberg ZA. Washington University School of Medicine, St. Louis, MO; Cedars-Sinai Medical Center, Los Angeles, CA; Mary Crowley Cancer Research, Dallas, TX; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; University of Texas Health San Antonio Cancer Center, San Antonio, TX; University of Miami, Miami, FL; Mayo Clinic, Phoenix, AZ; Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Molecular Templates, Inc., Jersey City, NJ; Molecular Templates, Inc., Austin, TX; Translational Research in Oncology, Montevideo, Uruguay; UCLA David Geffen School of Medicine, Los Angeles, CA.
P2-13-46 Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
Diéras V, Deluche E, Lusque A, Pistilli B, Bachelot T, Pierga J-Y, Viret F, Levy C, Salabert L, Le Du F, Dalenc F, Jouannaud C, Venat-Bouvet L, Jacquin J-P, Durando X, Petit T, Mahier - Aït Oukhatar C, Filleron T, Mosele MF, Lacroix-Triki M, Ducoulombier A, André F. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France; Department of Medical Oncology, CHU Dupuytren, Limoges, France; Department of Biostatistics, Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Department of Medical Oncology, Institut Curie Paris & Saint Cloud, Université de Paris, Paris, France; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France; Department of Medical Oncology, Centre François Baclesse, Caen, France; Department of Medical Oncology, Bergonie Institute, Bordeaux, France; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Department of Medical Oncology, Institut Jean Godinot, Reims, France; Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont Ferrand, France; Department of Medical Oncology, Institut de Cancérologie de Strasbourg - Europe, Strasbourg, France; R&D Unicancer, Paris, France; Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
P2-13-47 Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results
Zhang J, Ji D, Shen W, Xiao Q, Gu Y, O’Shaughnessy J, Xia G, Ji Y, Xiong G, Li M, Xu D, Cartmell R, Song C, Yan J, Hu X. Fudan University Shanghai Cancer Center, Shanghai Medical College, Department of Oncology, Department of Medical Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University Shanghai Cancer Center, Department of Radiology, Shanghai, China; Baylor University Medical Center, Texas Oncology, Dallas, TX; Novocodex Biopharmaceuticals, Shaoxing, China; NovocodexBiopharmaceutical, Shaoxing, China6Ambrx, Princeton, NJ.
P2-13-48 Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine
Jiang Z, Yan M, Bian L, Wang T, Hu X, Zhang Q, Ouyang Q, Feng J, Yin Y, Sun T, Tong Z, Wang X, Yao H, Jiang S, Zhu X, Zou J. The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; Fudan University Shanghai Cancer Center, Shanghai, China; Harbin Medical University Cancer Hospital, Harbin, China; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Liaoning Cancer Hospital and Institute, Shenyang, China; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Zhejiang Cancer Hospital, Hangzhou, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
P2-13-49 Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer
Veeraraghavan J, Bose S, Mistry R, Selenica P, Nanda S, Qin L, Gazzo A, Zhu Y, Mancini MA, tossi F, Weigelt B, Reis-Filho JS, Osborne CK, Rimawi MF, Schiff R. Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, and Department of Medicine, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, and Departments of Medicine, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
P2-13-51 Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter DA, Roesch E, Yau C, Lu R, Wolf D, Samson S, Stafford D, Albain KS, Isaacs C, Trivedi M, Yee D, Boughey J, Thomas1 A, Chien AJ, Hylton N, Li W, DeMichele A, Perlmutter J, Symmans WF, Hershman DL, Melisko M, van 't Veer LJ, Wilson A, Asare SM, Berry DA, Schwab R, Rugo HS Esserman LJ. Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Cleveland Clinic, Cleveland, OH; University of California, San Francisco, San Francisco, CA; Quantum Leap Healthcare Collaborative, San Francisco, CA; Breast Oncology Program, Breast Science Advocacy Core (BSAC), University of California, San Francisco, San Francisco, CA; Loyola University Chicago Stritch School of Medicine, Maywood, IL; Georgetown University Lombardi Cancer Center, Washington, DC; Columbia University Medical Center, New York, NY; Mayo Clinic Breast Cancer Center, Rochester, MN; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC; University of Pennsylvania, Philadelphia, PA; Gemini Group, Ann Arbor, MI; University of Texas, M.D. Anderson Cancer Center, Houston, TX; Berry Consultants, LLC, Austin, TX; University of California, San Diego, San Diego, CA.
   
  Treatment - Therapeutic Strategies: Immunotherapy (Clinical)
P2-14-01 Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
Han HS, Costa R, Armaghani A, Soyano A, Loftus L, Soliman H, Fridley B, Whiting J, Cerezo A, Rosa M, Extermann M, Khong H, Czerniecki B. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
P2-14-02 Overall survival following treatment with a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
Williams W, Dakhil SR, Calfa C, Holmes JP, Bhattacharya S, Lukas J, Tan-Chui E, Peoples GE, Sunkari VG, Lacher MD, Wiseman CL. BriaCell Therapeutics Corporation, Berkeley, PA; Cancer Center of Kansas, Wichita, KS; University of Miami, Miami, FL; Redwood Reg Medical Grp, Santa Rosa, CA; Thomas Jefferson University, Philadelphia, PA; The Everett Clinic, Everett, WA; Florida Cancer Specialists and Research Institute, Parkland, FL; Cancer Insight, San Antonio, TX; BriaCell Therapeutics Corporation, Havertown, PA.
P2-14-03 A pilot study of paclitaxel plus pembrolizumab in patients with metastatic HER2-negative breast cancer (PePPy)
Tan AR, S. Chai J, Robinson MM, Hellner LB, Gavini N, Sulai N, Turner JD, Atlas J, Graham DL, Induru RR, Kadakia KC, Vallabhaneni GD, Heeke AL, Foureau DM, Fisher JG. Levine Cancer Institute, Atrium Health, Charlotte, NC.
P2-14-04 Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial
Chen L, Jiang Y-Z, Wu S, Wu J, Di G, Liu G, Yu K, Fan L, Li J, Hou Y, Hu Z, Chen C, Huang X, Cao A, Hu X, Zhao S, Ma X, Zhu X, Zou J, Yang W, Wang Z, Shao Z-m. Fudan University Shanghai Cancer Center, Shanghai, China; Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
P2-14-05 Emerging molecular variants by circulating tumor DNA after immunotherapy in metastatic breast cancer
Kang AK, Shah AN, Katam N, Davis AA, Gerratana L, Chandra S, Jacob S, Shi M, Srivastava J, D’Amico P, Reduzzi C, Gurley M, Wehbe F, Zhang Q, Behdad A; Cristofanilli M. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Washington University School of Medicine, St. Louis, MO; University of California San Francisco, San Francisco, CA.
P2-14-06 Durable responses with intratumoral electroporation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890
Telli ML, Wapnir I, Devitt B, Cuff K, Soliman H, Vinayak S, Canton DA, Twitty CG, Xie S, Lu Y, Bannavong D, O'Keeffe B, Aung S, Joshi R. Standford University School of Medicine, Stanford, CA; Stanford University School of Medicine, Stanford, CA; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia; Princess Alexandra Hospital, Queensland, Australia; Moffitt Cancer Center, Tampa, FL; University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, Seattle, WA; OncoSec Medical, San Diego, CA; Adelaide Oncology and Haematology, Adelaide, Australia.
P2-14-07 Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer
Chun B, Lutz ER, Rudraraju L, DeOliveira E, Seiz A, Shah M, Borrello I, Fredrich NE, Noonan K, Page DB. Earle A. Chiles Research Institute, Portland, OR; WindMIL Therapeutics, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, MD.
P2-14-08 Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial
Liu J, Tian Z, Wang Y, Lin Y, Li H. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Department of Breast and Thyroid Surgery, First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-sen University, Guangzhou, China; Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, China.
P2-14-09 Withdrawn
P2-14-11 Immune response monitoring in breast cancer patients treated with neoadjuvant chemotherapy combined with dendritic cell vaccines
Hato L, Inogés S, Pérez B, Mejías L, Sánchez-Bayona R, Santisteban M, López A. Clinica Universidad de Navarra, Pamplona, Spain.
P2-14-12 B-immune interim analysis: A phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
Carrasco J, Quaghebeur C, Henry S, Galant C, Van Bockstal M, Delrée P, Honhon B, Korman D, Verschaeve V, Lonchay C, Levefre S, D'hondt L, Berliere M, Delmarcelle S, Mine J-M, Willems T, Müller G, Myant N, Bar I, Constant M, Haussy S, Devaux A, Coulie P, Canon J-L, Duhoux F. Departement of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium; Departement of Medical Oncology, CHU UCL Namur, site Saite Elisabeth, Namur, Belgium; Department of Pathology, Cliniques Universitaires Saint Luc, Brussels, Belgium; Institut de Pathologie et Génétique, IPG, Gosselies, Belgium; Departement of Medical Oncology, UCL Namur, Site Mont Godinne, Yvoir, Belgium; Department of Oncology, Breast Clinic, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium; Departement of Pharmacy, Grand Hôpital de Charleroi, Charleroi, Belgium; Departement of Gynecology, Grand Hôpital de Charleroi, Charleroi, Belgium; Laboratory of Translational Oncology, LTO, Gosselies, Belgium; de Duve Institute, UCL, Brussels, Belgium.
P2-14-13 Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis
Pascual T, Vidal M, Oliveira M, Cejalvo JM, Vega E, Sanfeliu E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, de la Cruz L, Falato C, Juan M, Ferrero-Cafiero JM, González-Farré1 X, Villagrasa P, Prat A. SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital Clínic de Barcelona/SOLTI Breast Cancer Research Group, Barcelona, Spain; Vall d'Hebron University Hospital/ SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital Clínico Universitario de Valencia/INCLIVA, Valencia, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Vall d'Hebron University Hospital, Barcelona, Spain; Centro Integral Oncológico Clara Campal, Barcelona, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital Universitari General de Catalunya/ SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital Clínic de Barcelona/ SOLTI Breast Cancer Research Group, Barcelona, Spain.
P2-14-14 Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2 negative stage II-III breast cancer
Garber HR, Basu S, Jindal S, Raghavendra AS, Santiago L, Adrada BE, Sharma P, Allison JP, Litton J. UT MD Anderson Cancer Center, Houston, TX.
P2-14-15 Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Makhoul I, Ibrahim SM, Abu-Rmaileh M, Jousheghany F, Siegel E, Rogers LJ, Lee JJ, Pina-Oviedo S, Post GR, Beck T, Kieber-Emmons T, Monzavi-Karbassi B. University of Arkansas for Medical Sciences, Little Rock, AR.
P2-14-16 Withdrawn
P2-14-17 A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)
Isakoff SJ, Tung NM, Yin J, Tayob N, Parker J, Rosenberg J, Bardia A, Spring L, Park H, Collins M, Barry WT, Severgnini M, Peterkin D, Tolaney SM. Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dana Farber Cancer Institute, Boston, MA; McConnell Consulting, Evergreen, CO; J. Rosenberg, MD Consulting Group, LLC, Sanibel, FL; OncoPep, North Andover, MA.
P2-14-18 A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
Garrido-Castro AC, Graham N, Bi K, Park J, Fu J, Keenan T, Richardson ET, Pastorello R, Lange P, Attaya V, Wesolowski R, Sinclair N, Lucas Z, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Briccetti F, Toke M, Chen W, Wucherpfennig K, Marx S, Tian Y, Agudo J, Guerriero JL, Schnitt S, Lin NU, Winer EP, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM. Dana-Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women's Hospital, Boston, MA; Ohio State University Hospital, Columbus, OH; Northern Light, Eastern Maine Medical Center, Bangor, ME; Stamford Hospital, Stamford, CT; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont Medical Center, Burlington, VT; UMass Memorial Medical Center, Worcester, MA.
   
  Treatment - Therapeutic Strategies: Neoadjuvant Endocrine Therapy
P2-15-01 Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer
Lopez Velazco JI, Otaño M, Lacambra I, Elorriaga K, Lahuerta A, Martínez A, Segur V, Manzano S, Prat A, Caffarel M, Urruticoechea A. Biodonostia Health Research Institute, San Sebastían, Spain; Guipúzcoa Cancer Clinical Management Unit/OSI Donostialdea – Onkologikoa, San Sebastían, Spain; Hospital Clinic University of Barcelona, Barcelona, Spain; IKERBASQUE, Basque Foundation for Science and Biodonostia Health Research Institute, Bilbao-San Sebastían, Spain; Guipúzcoa Cancer Clinical Management Unit/OSI Donostialdea – Onkologikoa and Biodonostia Health Research Institute, San Sebastían, Spain.
P2-15-02 Using Oncotype DX Breast Recurrence Score® (RS) assay to define the role of neoadjuvant endocrine therapy (NET) in early-stage hormone receptor positive (HR+) breast cancer (BC)
Taylor C, Foreman A, Russell C, Bandyopdhyay D, Deng X, Floyd L, Zelnak A, O'Regan R, Bear H, Meisel J. Emory, Atlanta, GA; Exact Sciences Corporation, Redwood City, CA; Virginia Commonwealth University, Richmond, VA; Atlanta Cancer Care, Atlanta, GA; University of Rochester, Rochester, NY.
P2-15-03 Neoadjuvant endocrine therapy (NET) as bridge therapy for early stage breast cancer during COVID-19: A single institution experience
Huang J, Feinberg J, Dabiri B, Baum J, Akerman M, Pasquarella A, Rohatgi A, Dhage A, Guth A, D'Abreo N. NYU Langone Hospital - Long Island, Mineola, NY; NYU Langone Hospital, New York, NY.